Herpes Labialis News and Research

RSS
Herpes labialis or "orolabial herpes" is an infection of the lip by herpes simplex virus. An outbreak typically causes small blisters or sores on or around the mouth commonly known as cold sores or fever blisters.
Results from a nested randomized controlled trial for BCG vaccination against recurrent herpes labialis

Results from a nested randomized controlled trial for BCG vaccination against recurrent herpes labialis

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Research team develops a new decoding method for viral genes

Research team develops a new decoding method for viral genes

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma initiates maribavir Phase 2 program for CMV infections

GSK launches Medivir's Xerclear for OTC use in Europe

GSK launches Medivir's Xerclear for OTC use in Europe

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

Watson introduces Famciclovir tablets to treat cold sores, genital herpes

Watson introduces Famciclovir tablets to treat cold sores, genital herpes

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

New American Therapeutics acquires U.S. rights to market Denavir drug

New American Therapeutics acquires U.S. rights to market Denavir drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.